New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:55 EDTACAD, ACAD, ATTU, ATTU, CODE, CODE, AERI, AERI, EGAN, EGAN, IMAX, IMAX, SPNS, SPNS, JAKK, JAKK, CNAT, CNAT, BIRT, BIRT, BDSI, BDSI, PERI, PERIRoth Capital to hold a conference
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 10 at 11 am; not all company presentations may be webcasted. Webcast Link
News For ACAD;BDSI;BIRT;CNAT;JAKK;SPNS;IMAX;EGAN;AERI;CODE;ATTU;PERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:43 EDTJAKKFly Watch: 'Force Friday' seen awakening shares of Disney, Hasbro
Subscribe for More Information
09:40 EDTACADACADIA U.S. introduction of Nuplazid likely in 2016, says Ladenburg
Subscribe for More Information
07:04 EDTACADACADIA submits NDA for Nuplazid for treatment of Parkinson's Disease psychosis
Subscribe for More Information
07:04 EDTACADACADIA names Steve Davis president, CEO
ACADIA Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and CEO. Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015. Davis has also been appointed to the ACADIA Board of Directors.
September 2, 2015
10:56 EDTATTUAttunity Ltd management to meet with Craig Hallum
Subscribe for More Information
06:50 EDTIMAXIMAX China concerns provide an attractive entry point, says B. Riley
B. Riley said shares of IMAX are off by 30% since the mid-June peak given recent volatility in China. The firm said there is a low historical correlation with the economy and box office and notes China's box office trends remain strong. B. Riley said the weakness is an overreaction and provides an attractive entry point in shares. The firm rates IMAX a Buy with a $53 price target on shares.
05:48 EDTIMAXIMAX pullback brings attractive entry point, says B. Riley
B. Riley analyst Eric Wold attributes the 30% pullback in shares of IMAX since their mid-June peak to concerns around China. Investors are concerned that China's weak stock market could impact box office trends and put the planned IMAX China IPO at risk, Wold tells investors in a research note. The analyst, however, notes that correlations between economic changes and box office growth are historically very low, and that IMAX has a "strong" film slate for the remainder of the year. Further, he believes risk of a delayed IPO is already more than reflected in the shares. Wold points out his price target of $53 represents 75% upside from current share levels. He sees an attractive entry point and keeps a Buy rating on IMAX.
September 1, 2015
06:32 EDTJAKKJAKKS Pacific division secures licensing agreement with Moose Toys for Shopkins
Subscribe for More Information
August 31, 2015
08:48 EDTATTUAttunity Callidus poised to generate strong 2H15 returns, says Roth Capital
Roth Capital notes that the shares of Attunity (ATTU0 and Callidus (CALD) have outperformed versus their software peers recently. The firm expects software companies to report strong 2H15 results. Roth believes that the below peer valuations and recent outperformance of Attunity and Callidus indicate that they are poised to deliver strong returns in 2H15.
06:30 EDTJAKKDisguise and LEGO Group announces licensing agreement
Disguise, the Halloween costume division of toy manufacturer, JAKKS Pacific, announced that it has secured a licensing agreement with the LEGO Group to "construct" children's Halloween costumes, role play and accessories based on popular LEGO characters. The multi-year, multi-category agreement grants Disguise rights to distribute its LEGO licensed products across channels in North America, Europe, Korea and China. The LEGO costumes from Disguise are scheduled to be available at retailers in fall 2016.
August 27, 2015
10:00 EDTACADOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:37 EDTACADACADIA upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
August 26, 2015
15:05 EDTIMAXNew 'Star Wars' film will monopolize IMAX for a month, Hollywood Reporter says
Disney's (DIS) "Star Wars: The Force Awakens," which will be released December 18, will have four weeks of IMAX (IMAX) large-format screens to itself, according to the Hollywood Reporter, after IMAX reserved all of its screens for the movie for a month, something the company hasn't done since a similar deal with The Hobbit movies four years ago. Reference Link
10:11 EDTJAKKHigh option volume stocks
Subscribe for More Information
August 25, 2015
17:16 EDTJAKKJAKKS Pacific: Court requires parties to provide notice of derivative settlement
JAKKS Pacific announced that the United States District Court for the Central District of California has authorized notice to be given to JAKKS' shareholders of the Court's preliminary approval of the previously disclosed settlement of Vladimir Gusinsky Living Trust v. Stephen Berman, et al. (f/k/a Advanced Advisors G. P. v. Stephen Berman, et al.) Case No. 2-14-cv-01420-JAK (SSx), a consolidated shareholder derivative action. The proposed settlement is subject to final Court approval, and the Court has set a final approval hearing for November 2, 2015, at 8:30 a.m. PT, in the courtroom of the Honorable John A. Kronstadt, United States District Judge. At the November 2, 2015 hearing, the Court will also hear a request from plaintiff's counsel for an award of attorneys' fees and expenses.
09:59 EDTACADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:07 EDTACADACADIA initiated with a Buy at Aegis
Subscribe for More Information
August 21, 2015
16:38 EDTACADACADIA unit manufacturing agreement with BASF Pharma
On August 17, our Swiss subsidiary, ACADIA Pharmaceuticals GmbH, entered into a co-operation agreement and product schedule, collectively referred to as the manufacturing agreement, with BASF Pharma SA, or BASF. Under the manufacturing agreement, BASF has agreed to manufacture and supply pimavanserin tartrate, the active pharmaceutical ingredient of NUPLAZID, for commercial use. The term of the manufacturing agreement extends through December 31, 2020 and will automatically renew for subsequent one year terms unless either party provides timely notice of its intent not to renew, or unless the manufacturing agreement is terminated earlier pursuant to its terms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use